Business Segment Information (Details) (USD $) In Thousands, unless otherwise specified	3 Months Ended				6 Months Ended
	Oct. 31, 2013		Oct. 31, 2012		Oct. 31, 2013		Oct. 31, 2012
Net revenue	$ 2,383		$ 1,458		$ 5,403		$ 3,564
Sales and marketing costs	(698)		(680)		(1,340)		(1,389)
Stock- based compensation expense	(476)		(624)		(1,028)		(1,364)
Personalized Oncology Solutions [Member]
Net revenue	623		459		1,245		1,377
Direct cost of services	(726)		(576)		(1,470)		(1,293)
Sales and marketing costs	(423)		(378)		(754)		(814)
Other operating expenses	0		0		0		0
Stock- based compensation expense	0	[1]	0	[1]	0	[1]	0	[1]
Segment profit (loss)	(526)		(495)		(979)		(730)
Translational Oncology Solutions [Member]
Net revenue	1,760		999		4,158		2,187
Direct cost of services	(696)		(471)		(1,566)		(1,162)
Sales and marketing costs	(213)		(241)		(460)		(432)
Other operating expenses	(673)		(433)		(1,063)		(794)
Stock- based compensation expense			0	[1]	0	[1]	0	[1]
Segment profit (loss)	178		(146)		1,069		(201)
Unallocated Corporate Overhead [Member]
Net revenue	0		0		0		0
Direct cost of services	0		0		0		0
Sales and marketing costs	0		0		0		0
Other operating expenses	(877)		(651)		(1,534)		(1,221)
Stock- based compensation expense	(476)	[1]	(624)	[1]	(1,028)	[1]	(1,364)	[1]
Segment profit (loss)	(1,353)		(1,275)		(2,562)		(2,585)
Consolidated [Member]
Net revenue	2,383		1,458		5,403		3,564
Direct cost of services	(1,422)		(1,047)		(3,036)		(2,455)
Sales and marketing costs	(636)		(619)		(1,214)		(1,246)
Other operating expenses	(1,550)		(1,084)		(2,597)		(2,015)
Stock- based compensation expense	(476)	[1]	(624)	[1]	(1,028)	[1]	(1,364)	[1]
Segment profit (loss)	$ (1,701)		$ (1,916)		$ (2,472)		$ (3,516)

[1] Stock compensation expense is shown separately and is excluded from direct costs of services, sales and marketing costs, and other operating expenses, as it is managed on a consolidated basis and is not used by management to evaluate the performance of its segments.